Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 11/20 | 0.68 |
| ▸ | RARA | P10276 | 10/20 | 0.68 |
| ▸ | RARB | P10826 | 10/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25747756 | 0.92 | RARG (0.72) | RARGRARARARBSLC6A9 | |
| SCHEMBL382029 | 0.91 | RARG (0.83) | RARGRARARARB | |
| SCHEMBL381496 | 0.90 | RARG (0.68) | RARGRARARARBMAPT | |
| SCHEMBL25040287 | 0.90 | RARG (0.70) | RARGRARARARBL3MBTL1SLC6A9 | |
| SCHEMBL30244992 | 0.89 | RARG (0.64) | RARGRARARARBMAPTALDH1A1 | |
| SCHEMBL382222 | 0.89 | RARG (0.66) | RARGRARARARBMEN1KMT2A | |
| SCHEMBL25038342 | 0.89 | RARG (0.64) | RARGRARARARBMAPTALDH1A1 | |
| SCHEMBL26199872 | 0.88 | RARG (0.78) | RARGRARARARBKDM4EHTT | |
| SCHEMBL23439863 | 0.87 | RARG (0.66) | RARGRARARARBL3MBTL1SLC6A9 | |
| SCHEMBL25747806 | 0.86 | RARG (0.64) | RARGRARARARBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-09-07 | — | — | US | disclosed |
| US-11691946-B2 | Preparation of Trifarotene and intermediates and polymorphs thereof | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-07-04 | — | — | US | disclosed |
| US-11691946-B2 | Preparation of Trifarotene and intermediates and polymorphs thereof | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | UGT1A4, TBK1, UGT1A7 | RARG 761/4885RARA 640/4885RARB 461/4885 |
| US-11691946-B2 | Preparation of Trifarotene and intermediates and polymorphs thereof | UGT1A4, TBK1, UGT1A7 | RARG 761/4885RARA 640/4885RARB 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.